Dehaier Medical Systems said today it is partnering with China Sciences Group to provide its wearable sleep apnea products to the Chinese pension and health industry through China Science’s elder care platform. Dehaier is joining China Sciences and Chia Tai Pharmaceutical Group to launch a cooperative “Elderly Sleep Apnea Comprehensive Disease Solution Project” to bring medical […]
Dehaier Medical Systems (NSDQ:DHRM) said today that a Chinese mobile Internet firm, Hangzhou Liaison Interactive Information Technology (SHE:002280), took out a $20 million stake. The $1.80-per-share deal is a 35% premium on Dehaier’s $1.33 closing price yesterday. It includes warrants for 1 million shares exercisable at $2.20 apiece and is expected to close by June 30, Dehaier […]
Share prices for China’s Dehaier Medical Systems (NSDQ:DHRM) jumped today after it released preliminary numbers for last year, despite massive losses incurred as it sheds unprofitable medical device businesses. Beijing-based Dehaier said in February that it plans to ditch the medtech units to focus on its wearable sleep respiratory business. Today the company reported preliminary losses of -$36 […]
China’s Dehaier Medical Systems (NSDQ:DHRM) said today that it plans to ditch its unprofitable medical device businesses so it can focus on its wearable sleep respiratory business. Dehaier said it plans to form a new subsidiary called Connection Wearable Health Technology by the end of this month, aiming to focus on “wearable sleep respiratory and mobile […]
Dehaier Medical said today it received a $20 million equity investment offer from Hangzhou Liaison Interactive Information Technology for 10 million newly issued common shares at $2 per share. Dehaier, who markets and sells medical devices and respiratory products in China and internationally, said it assembled a special committee to consider the investment proposal. None […]
Earlier this week a company director, Frederick Moll, picked up another 5,000 shares at $24.15 each, representing the 1st insider buy on the open market since late last year.
Edwards Lifesciences (NYSE:EW) said it will re-state its financial results for the first 3 quarters of 2011, “due to certain technical errors in the balance sheets and cash flow statements for these interim periods.”
The Irvine, Calif.-based heart valve maker said the errors involve the mis-statement of short-term investments as cash & equivalents, plus the way it treated tax benefits from stock plans.
Roche (PINK:RHHBY) won clearance from the U.S. Food & Drug Administration for its Accu-Chek Nano SmartView blood glucose monitoring system.
The Switzerland-based biotech builder’s no code meter is smaller than a credit card that allows patients to customize test reminders, pre and post meal markers and calculate their average glucose levels.